Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products

Current version

PDF iconRevision 2 - Position statement

Reference number CHMP/BWP/303353/2010
Published 28/06/2011
Keywords Creutzfeldt-Jakob disease, human transmissible spongiform encephalopathies, plasma-derived medicinal products, urine-derived medicinal products, sporadic CJD, genetic CJD, iatrogenic CJD, variant CJD, blood infectivity, transmissibility
Description This document addresses the safety of plasma-derived and urine-derived medicinal products with respect to Creutzfeldt-Jakob disease (CJD). It gives special consideration to variant Creutzfeldt-Jakob disease (vCJD) infectivity.

Document history

Revision 2

Current version

PDF iconPosition statement


PDF iconOverview of comments


PDF iconDraft position statement


PDF iconConcept paper

Published: 28/06/2011


Published: 28/06/2011


Published: 27/07/2010


Published: 23/07/2009

Revision 1 PDF iconPosition statement Published: 23/06/2004
First version PDF iconPosition statement Published: 20/02/2003
Superseded document PDF iconPosition statement Published: 25/02/1998

Related content

How useful was this page?

Add your rating